ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. is recruiting a seasoned executive to oversee Senior Scientific’s next stage of product development for its MRX diagnostic technology for the early detection of cancer. The new President and COO candidate under consideration, has a strong background in the life sciences and experience in diagnostic medical product development. The new President/COO will be responsible for expanding the collaborations in place with the MD Anderson Cancer Center in Houston and The University of New Mexico Health Sciences Center, Albuquerque, to help further develop this technology.
Additional details will be made public when the contract is finalized and executed. Gerald Grafe, current president of Senior Scientific, will remain with the Company to focus on strategic relationships and intellectual property issues. Edward R. Flynn, PhD, founder of Senior Scientific, will remain as Chief Scientist.
Gerald Grafe, current president of Senior Scientific, said, “The time has come to expand our business from early stages of technology development to demonstrating the ultimate value. For this, we need the leadership of an experienced executive with a history of accomplishment in medical market product development. Fortunately, we have identified an excellent candidate, and we expect to be able to announce his appointment in the near future.”
Manny Tsoupanarias, CEO of Manhattan Scientifics, said, “We are grateful for the leadership that Gerald Grafe has given Senior Scientific over the past several years. He has moved the Company significantly forward in a number of critical areas. We are pleased that he will remain a key member of the team as we seek to move into a new stage of development. We believe the Company’s future is highly promising and we are quite excited about our future."
Marvin Maslow, founder of Manhattan Scientifics, said, “Over the past few years, Gerald and Dr. Flynn have provided the leadership to build on Dr. Flynn’s serious foundation work, establishing the Company’s technology base with nanoparticle manufacturing and multiple instruments; our collaboration with MD Anderson and the UNM Health Sciences Center and Cancer Center, including the delivery of an MRX diagnostic instrument; our ever-expanding intellectual property portfolio; and our interaction with early investors. We look forward to updating investors about our new president and COO."
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.